2012年 · 第45卷第07期

Motor neuron disease is a neurodegenerative disease with unknown etiology, mainly involving motor neurons in the cerebral cortex, brain stem and spinal cord. It includes four clinical types: amyotrophic lateral sclerosis (ALS), progressive muscular atrophy, progressive bulbar palsy and primary lateral sclerosis. ALS is the most common type of motor neuron disease, and it is more common in middle-aged and elderly people. The main clinical manifestations are progressive aggravation of skeletal muscle weakness, atrophy, muscle fibrillation, bulbar paralysis and pyramidal tract sign, and the survival period is usually 3~5 years.

Insomnia is the most common type of sleep disorder in clinic. Long-term insomnia will have a serious negative impact on normal life and work, and even lead to malignant accidents^[1]。 In 2002, the epidemiological study of insomnia in 10 countries worldwide (questionnaire survey) showed that 45.4% of Chinese people had experienced insomnia in different degrees in the past month^[2]。 In order to standardize the clinical application of insomnia treatment drugs, the Insomnia Diagnosis and Treatment Consensus Expert Group drafted the Chinese Expert Consensus on the Definition, Diagnosis and Drug Treatment of Insomnia in 2004, which was officially published in 2006 after many revisions. This consensus has played an important guiding role in standardizing the clinical diagnosis and treatment of insomnia. In 2010, the Sleep Disorder Group of Neurology Branch of Chinese Medical Association invited experts from relevant disciplines to form the diagnosis and treatment guidelines for adult insomnia in China after many discussions according to the principles of evidence-based medicine, referring to the relevant progress data in the field of insomnia diagnosis and treatment in recent years, and combining with China's national conditions, aiming to provide clinicians with a standardized framework for adult insomnia diagnosis and treatment. In the course of clinical practice, physicians should still carry out individualized treatment according to the specific condition of patients when referring to this guideline.

deep brain stimulation (DBS) therapy has become an effective method for the treatment of intermediate and advanced Parkinson's disease (PD). This therapy was first used in China in 1998, and it has been more than ten years since then. DBS therapy has significantly improved the motor symptoms and quality of life of PD patients. With the increase of the elderly population in China, the number of patients needing DBS therapy will further increase. In order to better standardize the indications and procedures of DBS therapy in China, and further strengthen the close cooperation and cooperation between neurology and surgery, this expert consensus is specially formulated.